Streetbeat News

Regulatory

INAB

IN8bio has announced that it will present biological correlative data from the ongoing Phase 1 clinical trial of INB-200, targeting newly diagnosed glioblastoma multiforme (GBM), and pre-clinical insights on its induced pluripotent stem cell (iPSC) gamma-delta T cell platform at the Society for Immunology of Cancer 38th Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 12:04 pm

ALB

Albemarle Corp. has agreed to pay the SEC over $103 million to settle violations of the Foreign Corrupt Practices Act. The settlement comes after an investigation into the company's practices overseas.

Portfolio Pulse from Charles Gross

September 29, 2023 | 12:00 pm

DASH

TKAYF

UBER

Uber Technologies Inc., DoorDash Inc., and Grubhub Inc. failed to overturn the New York City minimum wage increase, which mandates a minimum pay of $17.96 per hour for food delivery workers. The companies can either pay a straightforward hourly rate or opt for a per-delivery payment structure. The new legislation is set to introduce a second wage increment, bringing the hourly rate close to $20 by April 2025. Approximately 60,000 delivery workers in New York currently earn around $11 an hour post tips and expenses.

Portfolio Pulse from Shivani Kumaresan

September 29, 2023 | 11:52 am

AMRN

AZN

EWU

GSK

The European Medicines Agency (EMA) has agreed to add atrial fibrillation as a common side effect to product information for medicines containing Omega-3-acid Ethyl Esters. This decision could potentially impact companies such as AMRN, AZN, EWU, and GSK, which may have such medicines in their portfolio.

Portfolio Pulse from Charles Gross

September 29, 2023 | 11:43 am

SPY

House Democratic Leader Jeffries announced on CNBC that House Democrats would support the Senate's government funding bill to prevent a government shutdown.

Portfolio Pulse from Charles Gross

September 29, 2023 | 11:38 am

CAPR

Capricor Therapeutics has announced an update on its Type-B clinical meeting with the FDA regarding the design and execution of the HOPE-3 Phase 3 trial with lead asset CAP-1002 for Duchenne Muscular Dystrophy.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 11:35 am

GPCR

Structure Therapeutics' Phase 1b study of GSBR-1290 in overweight or obese individuals showed significant weight loss, supporting once-daily dosing. The drug also demonstrated a promising safety and tolerability profile.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 11:33 am

ABBV

AbbVie's Phase 3 CANOVA study of Venetoclax plus Dexamethasone for relapsed or refractory multiple myeloma did not meet its primary endpoint of significantly improved progression-free survival. Although patients receiving VenDex showed improvement in median PFS of 9.9 months compared to 5.8 months with the combination of study comparator pomalidomide and dexamethasone (PomDex), the results did not reach statistical significance.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 11:18 am

FXI

SPY

Senior diplomats from the U.S. and China met in Washington to discuss issues involving Taiwan Strait, Burma, and North Korea. This meeting has led to a premarket rise in U.S.-traded China stocks.

Portfolio Pulse from Charles Gross

September 29, 2023 | 10:48 am

BEEM

Beam Global has unveiled its new EV ARC Sustainable EV Charging Infrastructure Products, which are rated for 160 mph winds. The Federal General Services Administration (GSA) has designated these products as Disaster Preparedness Response & Recovery Products.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 10:04 am